Canada Markets close in 3 hrs 43 mins
  • S&P/TSX

    20,799.13
    +334.53 (+1.63%)
     
  • S&P 500

    4,580.80
    +67.76 (+1.50%)
     
  • DOW

    34,662.44
    +640.40 (+1.88%)
     
  • CAD/USD

    0.7809
    +0.0002 (+0.0273%)
     
  • CRUDE OIL

    66.58
    +1.01 (+1.54%)
     
  • BTC-CAD

    72,371.44
    -3,102.29 (-4.11%)
     
  • CMC Crypto 200

    1,438.19
    -0.69 (-0.05%)
     
  • GOLD FUTURES

    1,765.90
    -18.40 (-1.03%)
     
  • RUSSELL 2000

    2,189.25
    +41.83 (+1.95%)
     
  • 10-Yr Bond

    1.4600
    +0.0260 (+1.81%)
     
  • NASDAQ

    15,374.21
    +120.16 (+0.79%)
     
  • VOLATILITY

    28.41
    -2.71 (-8.71%)
     
  • FTSE

    7,129.21
    -39.47 (-0.55%)
     
  • NIKKEI 225

    27,753.37
    -182.25 (-0.65%)
     
  • CAD/EUR

    0.6902
    +0.0009 (+0.13%)
     

Myriad Genetics to Release Third Quarter Financial Results on November 2, 2021

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

SALT LAKE CITY, Oct. 27, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that it will hold its quarterly earnings conference call for the quarter ended September 30, 2021, at 4:30 p.m. EDT on Tuesday, November 2, 2021. The company’s quarterly earnings will be released the same day prior to the market opening. During the call, Paul J. Diaz, president and CEO, and R. Bryan Riggsbee, chief financial officer, will provide a financial overview and business update of Myriad Genetics’ performance for the third quarter of 2021.

The dial-in number for domestic callers is 1-800-920-2776. International callers may dial +1-212-271-4651. All callers will be asked to reference reservation number 21998401. An archived replay of the call will be available for seven days by dialing 1-800-633-8284 and entering the reservation number above. The conference call along with a slide presentation will be available through a live webcast at www.myriad.com.

About Myriad Genetics
Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and wellbeing for all, empowering individuals with vital genetic insights and enabling healthcare providers to better detect, treat and prevent disease. Myriad discovers and commercializes genetic tests that determine the risk of developing disease, assess the risk of disease progression, and guide treatment decisions across medical specialties where critical genetic insights can significantly improve patient care and lower healthcare costs. For more information, visit the Company's website: www.myriad.com.

Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice CDx, EndoPredict, Prequel, Foresight, GeneSight, riskScore and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries.

Media Contact:

Investor Contact:

Megan Manzari

Nathan Smith

(315) 730-2379

(801) 505-5067

Megan.Manzari@myriad.com

Nathan.Smith@myriad.com



Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting